Abnormal cytology in oropharyngeal brushings and in oral rinses is not associated with HPV infection: The OHMAR study.
Adult
Aged
Alphapapillomavirus
/ genetics
Cytodiagnosis
/ methods
DNA, Viral
/ analysis
Follow-Up Studies
Homosexuality, Male
/ statistics & numerical data
Humans
Longitudinal Studies
Male
Middle Aged
Mouth
/ metabolism
Mouthwashes
/ metabolism
Oropharynx
/ metabolism
Papillomavirus Infections
/ metabolism
Prognosis
Young Adult
HIV
brushing
human papillomavirus (HPV)
liquid-based cytology
men who have sex with men (MSM)
oral rinse
oropharyngeal neoplasms
Journal
Cancer cytopathology
ISSN: 1934-6638
Titre abrégé: Cancer Cytopathol
Pays: United States
ID NLM: 101499453
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
04
02
2020
revised:
02
04
2020
accepted:
05
05
2020
pubmed:
3
6
2020
medline:
23
2
2021
entrez:
3
6
2020
Statut:
ppublish
Résumé
No screening is available for human papillomavirus (HPV)-associated oropharyngeal cancers. The authors investigated whether cytology may be used as a screening tool and whether oral HPV infection is associated with cytologic abnormalities detected in oropharyngeal brushings and in oral rinse-and-gargle specimens from asymptomatic individuals at increased risk for oral HPV infection. Specimens were collected from men who have sex with men at 6-month intervals. Oropharyngeal samples and oral rinse-and-gargle specimens were collected using a cytobrush and mouthwash, respectively. Exfoliated cells were dispersed in PreservCyt. Liquid-based slides were stained with Papanicolaou. An HPV genotyping test using a linear array was used for HPV detection. Associations with abnormal cytology were investigated using logistic regression. Overall, 631 brushings and 802 rinses collected from 310 individuals were evaluated; of these specimens, 2 brushings (0.3%) and 10 rinses (1.2%) were inadequate for morphologic evaluation. Of the adequate samples, 35 of 629 brushings (5.5%) and 19 of 792 rinses (2.4%) were abnormal. No associations of high-risk HPVs or HPV-16 infection with cytologic abnormalities were observed for oropharyngeal brushings (high-risk HPVs: odds ratio [OR], 1.19; 95% CI, 0.41-3.50; P = .75; HPV-16: OR, 0.76; 95% CI, 0.10-5.84; P = .79) or for oral rinses (high-risk HPVs: OR, 1.13; 95% CI, 0.26-4.98; P = .87; HPV-16: OR, 0.62; 95% CI, 0.04-10.60; P = .74). Concurrent moderate/heavy drinking and smoking significantly increased the risk of cytologic abnormalities in the brushings (hazard ratio, 4.84; 95% CI, 1.15-20.43; P = .03). Oral HPV infection by high-risk HPVs and HPV-16 does not confer an increased risk of cytologic abnormalities in oropharyngeal brushings and oral rinses. Abnormal cytology seems to be associated with smoking and drinking habits.
Sections du résumé
BACKGROUND
No screening is available for human papillomavirus (HPV)-associated oropharyngeal cancers. The authors investigated whether cytology may be used as a screening tool and whether oral HPV infection is associated with cytologic abnormalities detected in oropharyngeal brushings and in oral rinse-and-gargle specimens from asymptomatic individuals at increased risk for oral HPV infection.
METHODS
Specimens were collected from men who have sex with men at 6-month intervals. Oropharyngeal samples and oral rinse-and-gargle specimens were collected using a cytobrush and mouthwash, respectively. Exfoliated cells were dispersed in PreservCyt. Liquid-based slides were stained with Papanicolaou. An HPV genotyping test using a linear array was used for HPV detection. Associations with abnormal cytology were investigated using logistic regression.
RESULTS
Overall, 631 brushings and 802 rinses collected from 310 individuals were evaluated; of these specimens, 2 brushings (0.3%) and 10 rinses (1.2%) were inadequate for morphologic evaluation. Of the adequate samples, 35 of 629 brushings (5.5%) and 19 of 792 rinses (2.4%) were abnormal. No associations of high-risk HPVs or HPV-16 infection with cytologic abnormalities were observed for oropharyngeal brushings (high-risk HPVs: odds ratio [OR], 1.19; 95% CI, 0.41-3.50; P = .75; HPV-16: OR, 0.76; 95% CI, 0.10-5.84; P = .79) or for oral rinses (high-risk HPVs: OR, 1.13; 95% CI, 0.26-4.98; P = .87; HPV-16: OR, 0.62; 95% CI, 0.04-10.60; P = .74). Concurrent moderate/heavy drinking and smoking significantly increased the risk of cytologic abnormalities in the brushings (hazard ratio, 4.84; 95% CI, 1.15-20.43; P = .03).
CONCLUSIONS
Oral HPV infection by high-risk HPVs and HPV-16 does not confer an increased risk of cytologic abnormalities in oropharyngeal brushings and oral rinses. Abnormal cytology seems to be associated with smoking and drinking habits.
Substances chimiques
DNA, Viral
0
Mouthwashes
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
648-655Informations de copyright
© 2020 American Cancer Society.
Références
Saulle R, Semyonov L, Mannocci A, et al. Human papillomavirus and cancerous diseases of the head and neck: a systematic review and meta-analysis. Oral Dis. 2015;21:417-431.
Agalliu I, Gapstur S, Chen Z, et al. Associations of oral alpha-, beta-, and gamma-human papillomavirus types with risk of incident head and neck cancer. JAMA Oncol. 2016;2:599-606.
de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141:664-670.
Castellsague X, Alemany L, Quer M, et al. HPV involvement in head and neck cancers: comprehensive assessment of biomarkers in 3680 patients. J Natl Cancer Inst. 2016;108:djv403.
Haeggblom L, Attoff T, Yu J, et al. Changes in incidence and prevalence of human papillomavirus in tonsillar and base of tongue cancer during 2000-2016 in the Stockholm region and Sweden. Head Neck. 2019;41:1583-1590.
Wittekindt C, Wagner S, Bushnak A, et al. Increasing incidence rates of oropharyngeal squamous cell carcinoma in Germany and significance of disease burden attributed to human papillomavirus. Cancer Prev Res. 2019;12:375-382.
Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. J Clin Oncol. 2015;33:3235-3242.
Xu L, Dahlstrom KR, Lairson DR, Sturgis EM. Projected oropharyngeal carcinoma incidence among middle-aged US men. Head Neck. 2019;41:3226-3234.
Beachler DC, Kreimer AR, Schiffman M, et al. Multisite HPV16/18 vaccine efficacy against cervical, anal, and oral HPV infection. J Natl Cancer Inst. 2015;108:djv302. doi:10.1093/jnci/djv302
Hirth JM, Chang M, Resto VA, Guo F, Berenson AB; HPV Study Group. Prevalence of oral human papillomavirus by vaccination status among young adults (18-30 years old). Vaccine. 2017;35:3446-3451.
Chaturvedi AK, Graubard BI, Broutian T, et al. Effect of prophylactic human papillomavirus (HPV) vaccination on oral HPV infections among young adults in the United States. J Clin Oncol. 2018;36:262-267.
Lehtinen M, Apter D, Eriksson T, et al. Effectiveness of the AS04-adjuvanted HPV-16/18 vaccine in reducing oropharyngeal HPV infections in young females-results from a community-randomized trial. Int J Cancer. 2020;147:170-174. doi:10.1002/ijc.32791
Chaturvedi AK, Graubard BI, Broutian T, et al. Prevalence of oral HPV infection in unvaccinated men and women in the United States, 2009-2016. JAMA. 2019;322:977-979.
Shewale JB, Gillison ML. Dynamic factors affecting HPV-attributable fraction for head and neck cancers. Curr Opin Virol. 2019;39:33-40.
D'Souza G, McNeel TS, Fakhry C. Understanding personal risk of oropharyngeal cancer: risk-groups for oncogenic oral HPV infection and oropharyngeal cancer. Ann Oncol. 2017;28:3065-3069.
Gipson BJ, Robbins HA, Fakhry C, D'Souza G. Sensitivity and specificity of oral HPV detection for HPV-positive head and neck cancer. Oral Oncol. 2018;77:52-56.
Kreimer AR, Johansson M, Yanik EL, et al. Kinetics of the human papillomavirus type 16 E6 antibody response prior to oropharyngeal cancer. J Natl Cancer Inst. 2017;109:djx005. doi:10.1093/jnci/djx005
D'Souza G, Clemens G, Troy T, et al. Evaluating the utility and prevalence of HPV biomarkers in oral rinses and serology for HPV-related oropharyngeal cancer. Cancer Prev Res. 2019;12:689-700.
Fakhry C, Rosenthal BT, Clark DP, Gillison ML. Associations between oral HPV16 infection and cytopathology: evaluation of an oropharyngeal “Pap-test equivalent” in high-risk populations. Cancer Prev Res. 2011;4:1378-1384.
Dona MG, Giuliani M, Vocaturo A, et al. Cytology and human papillomavirus testing on cytobrushing samples from patients with head and neck squamous cell carcinoma. Cancer. 2014;120:3477-3484.
Rollo F, Latini A, Pichi B, et al. Prevalence and determinants of oral infection by human papillomavirus in HIV-infected and uninfected men who have sex with men. PLoS One. 2017;12:e0184623.
World Health Organization (WHO). International Agency for Research on Cancer (IARC) Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 100B-Biological Agents. A Review of Human Carcinogens. IARC; 2012.
Heath EM, Morken NW, Campbell KA, Tkach D, Boyd EA, Strom DA. Use of buccal cells collected in mouthwash as a source of DNA for clinical testing. Arch Pathol Lab Med. 2001;125:127-133.
Garcia-Closas M, Egan KM, Abruzzo J, et al. Collection of genomic DNA from adults in epidemiological studies by buccal cytobrush and mouthwash. Cancer Epidemiol Biomarkers Prev. 2001;10:687-696.
Dona MG, Pichi B, Rollo F, et al. Human papillomavirus detection in matched oral rinses, oropharyngeal and oral brushings of cancer-free high-risk individuals. Oral Oncol. 2019;91:1-6.
Gillison ML, Broutian T, Pickard RK, et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA. 2012;307:693-703.
King EM, Oomeer S, Gilson R, et al. Oral human papillomavirus infection in men who have sex with men: a systematic review and meta-analysis. PLoS One. 2016;11:e0157976.
Bettampadi D, Villa LL, Ponce EL, et al. Oral human papillomavirus prevalence and type distribution by country (Brazil, Mexico and the United States) and age among HPV infection in men study participants. Int J Cancer. 2020;146:3026-3033. doi:10.1002/ijc.32713
Franceschi S, Combes JD, Dalstein V, et al. Deep brush-based cytology in tonsils resected for benign diseases. Int J Cancer. 2015;137:2994-2999.
Vianna LMS, Carneiro FP, Amorim R, et al. Oropharynx HPV status and its relation to HIV infection. PeerJ. 2018;6:e4407. doi:10.7717/peerj.4407
Hashibe M, Brennan P, Benhamou S, et al. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst. 2007;99:777-789.
Hashibe M, Brennan P, Chuang SC, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev. 2009;18:541-550.
Chaturvedi AK, Anderson WF, Lortet-Tieulent J, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol. 2013;31:4550-4559.
Jansen L, Buttmann-Schweiger N, Listl S, et al. Differences in incidence and survival of oral cavity and pharyngeal cancers between Germany and the United States depend on the HPV-association of the cancer site. Oral Oncol. 2018;76:8-15.
World Health Organization (WHO). Global Status Report on Alcohol and Health 2018. WHO; 2018.
World Health Organization (WHO). WHO Global Report on Trends in Prevalence of Tobacco Smoking 2000-2025. 2nd ed. WHO; 2018.
Giles ML, Gartner C, Boyd MA. Smoking and HIV: what are the risks and what harm reduction strategies do we have at our disposal? AIDS Res Ther. 2018;15:26. doi:10.1186/s12981-018-0213-z
Beachler DC, Abraham AG, Silverberg MJ, et al. Incidence and risk factors of HPV-related and HPV-unrelated head and neck squamous cell carcinoma in HIV-infected individuals. Oral Oncol. 2014;50:1169-1176.
Picard A, Arowas L, Piroth L, Heard I, Ferry T; ORL-HIV-HPV Study Group. Head and neck squamous cell carcinoma in people living with HIV in France. Med Mal Infect. 2018;48:503-508.